


**In the claims:**

1. (Currently Amended) An amide derivative represented by the following formula [1] in any of the following cases (A) ~~and~~ or (B), or a salt thereof;




(A)

R<sup>1</sup> represents a saturated cyclic amino group (the saturated cyclic amino group may be substituted by 1 to 3 same or different members selected from the group consisting of alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl), monoalkylamino or dialkylamino;

R<sup>2</sup> represents alkyl, halogen, haloalkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, acyl, amino, monoalkylamino, dialkylamino, nitro, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl or cyano;

R<sup>3</sup> represents hydrogen, halogen or alkoxy;

Het1 represents any of groups of the following formulas [2] to [8];



Het2 represents pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl or 1, 2-dihydropyridazinyl (the Het2 may be substituted by 1 to 3 same or different members selected from the group consisting of alkyl, halogen and amino);

Excluding compound wherein  $R^1$  is (i) pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl, all of which may be substituted by 1 to 3 same or different members selected from the group consisting of alkyl, alkoxycarbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl, (ii) monoalkylamino, or (iii) dialkylamino, Het1 is a group of the formula [6], and Het2 is pyrazinyl or pyridyl which may be substituted by alkyl;

(B)

$R^1$  represents 4-methylpiperazin-1-yl, 1-pyrrolidinyl, piperidino, 4-ethylpiperazin-1-yl, 4-n-propylpiperazin-1-yl, cis-3, 5-dimethylpiperazin-1-yl, morpholino, dimethylamino or diethylamino;

R<sup>2</sup> represents methyl, halogen, trifluoromethyl, methoxy, methoxycarbonyl, nitro, dimethylcarbamoyl or cyano;

R<sup>3</sup> represents hydrogen, bromo or methoxy;

Het1 represents a group of the formula [6]; and

Het2 represents 3-pyridyl.

2. (Original) The amide derivative according to claim 1, or a salt thereof, wherein R<sup>1</sup> is a saturated cyclic amino group (the saturated cyclic amino group may be substituted by 1 to 3 same or different members selected from the group consisting of alkyl and alkoxy carbonyl), monoalkylamino or dialkylamino,

R<sup>2</sup> is alkyl, halogen, haloalkyl, alkoxy, alkoxy carbonyl, nitro, dialkylcarbamoyl or cyano,

R<sup>2</sup> is hydrogen, halogen or alkoxy,

Het1 is any of groups of the formulas [2] to [8], and

Het2 is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl or 1, 2-dihydropyridazinyl (the Het2 may be substituted by 1 to 3 same or different halogen).

3. (Currently Amended) The amide derivative according to claim 1, which is a compound selected from the group consisting of the following compounds (1) to (40), or a salt thereof:

(1) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino] phenyl}benzamide

(2) 3-iodo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino] phenyl}benzamide,

(3) 3-chloro-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin -2 -ylamino] phenyl}benzamide,

(4) 3-fluoro-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl}benzamide,

- (5) 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino] phenyl } benzamide,
- (6) 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl) pyrimidin-2-ylamino] phenyl} benzamide,
- (7) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(2-pyrazinyl) pyrimidin-2-ylamino] phenyl} benzamide,
- (8) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(6-chloropyridin-3-yl) pyrimidin-2-ylamino] -4-methylphenyl } benzamide,
- (9) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(5-bromopyridin-3-yl) pyrimidin-2-ylamino] -4-methylphenyl} benzamide,
- (10) 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methylphenyl } benzamide,
- (11) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(1,2-dihydropyridazin-4-yl) pyrimidin-2-ylamino] -4-methylphenyl } benzamide,
- (12) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridazinyl) pyrimidin-2-ylamino] phenyl } benzamide,
- (13) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl) pyrimidin-2-ylamino] phenyl } benzamide,
- (14) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyridin-2-ylamino] phenyl } benzamide.
- (15) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl) pyridin-2-ylamino] phenyl} benzamide.

- (16) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[2-(3-pyridyl) pyridin-6-ylamino] phenyl}benzamide,
- (17) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[3-(3-pyridyl) pyridin-5-ylamino] phenyl}benzamide,
- (18) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[3-(3-pyridyl) phenylamino] phenyl } benzamide,
- (19) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[2-(3-pyridyl) pyrazin-6-ylamino] phenyl}benzamide,
- (20) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[5-(3-pyridyl)-1,2,4-triazin-3-ylamino] phenyl}benzamide,
- (21) 3-methyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl}benzamide,
- (22) 4-(4-methylpiperazin-1-ylmethyl)-3-nitro-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl}benzamide,
- (23) 3-methoxy-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl}benzamide,
- (24) 3,5-dibromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl}benzamide,
- (25) 3,5-dimethoxy-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl}benzamide,
- (26) 3-(N,N-dimethylcarbamoyl)-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl}benzamide,

- (27) 3-bromo-4-(4-ethylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide,
- (28) 3-bromo-4-[4-(n-propyl)piperazin-1-ylmethyl]-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide,
- (29) 3-bromo-4-(N, N-dimethylaminomethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide,
- (30) 3-bromo-4-(N, N-diethylaminomethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide,
- (31) 3-bromo-4-(1-pyrrolidinylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide,
- (32) 3-bromo-4-(piperidinomethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide,
- (33) 3-bromo-4-(morpholinomethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide,
- (34) 3-bromo-4-(cis-3, 5-dimethylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide,
- (35) 3-bromo-4-(4-methyl-hexahydro-1H-1, 4-diazepin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl} benzamide,
- (36) 3-bromo-4-(1-piperazinylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl) pyrimidin-2-ylamino] phenyl} benzamide,
- (37) 4-[4-(t-butoxycarbonyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl) pyrimidin-2-ylamino] phenyl} benzamide,

(38) 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl) pyrimidin-2-ylamino]phenyl } benzamide,

(39) 3-methoxycarbonyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl}benzamide, and

(40) 3 -cyano-4-(4-methylpiperazin-1-ylmethyl)-N- { 4-methyl-3 - [4-(3 - pyridyl) pyrimidin-2-ylamino] phenyl}benzamide.

4. (Currently Amended) A pharmaceutical composition comprising the amide derivative of claim 1 or a salt thereof as an active ingredient and a pharmaceutically acceptable carrier.

5. - 8. (Cancelled)

9. (Previously Submitted) A method of treating a subject having acute lymphoblastic leukemia comprising administering to the subject an effective amount of the amide derivative of claim 1 or a salt thereof.

10. (Previously Submitted) A method of treating a subject having acute myelogenous leukemia comprising administering to the subject an effective amount of the amide derivative of claim 1 or a salt thereof.

11. (Previously Submitted) A method of treating a subject having acute myelogenous leukemia comprising administering to the subject an effective amount of the amide derivative of claim 1 or a salt thereof.